AI Patent Analysis Toolkit
PatentAgility
by KellDann

Examiner Nyrobi Celestine

Examiner Nyrobi Celestine appears to be about average relative to their peer examiners. Their lifetime grant ratio is 55.6%, they average 2.46 office actions per granted patent, and their rejection profile is dominated by ยง103.

Difficulty vs AU Very Easy
Difficulty vs Group About Average
Difficulty vs TC About Average
Difficulty vs USPTO About Average
Average OA / Grant 2.46
Export
Word PDF

Create account to export.

Examiner Details

Observed Examiner Years
6 years (2021-2026)
Phone
(571) 272-0129
Predicted Supervisor
N/A
Supervisor Phone
N/A
Tech Center
3700 - Mechanical Engineering, Manufacturing and Products
Group
3790 - Medical Instruments, Diagnostic Equipment, and Treatment Devices

Metrics

Applications Evaluated
304
Granted Applications
169
Non-Granted Applications
135
Avg OA / Grant
2.46
Last OA Observed
March 2026 (3 months ago)
Art Units Seen
3793 , 3798
Work Groups Seen

Context Comparison

Scope Examiners Lifetime Grant Ratio Avg OA / Grant
This Examiner 1 55.6% 2.46
Art Unit 13 35.1% 2.68
Group 327 40.3% 2.25
Tech Center 2,632 49.9% 2.01
USPTO 16,116 54.8% 1.98

Grant Timeline

0.0% 25.0% 50.0% 75.0% 100.0% 2021 2022 2023 2024 2025 2026
Shaded region marks the last two observed years, where grant outcomes may lag due to recency.
Year Applications Granted Grant Rate
No observed data before 2021; examiner may not yet have been active in the available dataset.
2021 23 12 52.2%
2022 51 42 82.4%
2023 58 43 74.1%
2024 67 59 88.1%
2025 87 13 14.9%
2026 18 0 0.0%

169 family-cache-validated grants; 0 OA-only grant signals.

Rejection Timeline

OA # Office Actions § 101 Percentage § 102 Percentage § 103 Percentage § 112 Percentage
1 293 0.0% 8.9% 82.3% 5.5%
2 202 0.5% 4.0% 80.2% 12.4%
3 102 0.0% 2.0% 83.3% 12.7%
4 41 0.0% 0.0% 80.5% 19.5%
5 15 0.0% 0.0% 73.3% 26.7%
6 4 0.0% 0.0% 75.0% 25.0%
7 3 0.0% 0.0% 66.7% 33.3%
8 2 0.0% 0.0% 100.0% 0.0%
9 1 0.0% 0.0% 100.0% 0.0%
10 1 0.0% 0.0% 100.0% 0.0%

§ 101 Yearly Trend

2024: AI Examples
2025: Aug. Memo
0.0%
2020
0.0%
2021
0.0%
2022
0.0%
2023
0.0%
2024
0.7%
2025
0.0%
2026

Each bar shows the share of this examiner's observed office actions in that year that included a § 101 rejection.